BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15687530)

  • 1. Effectiveness of acetylcysteine in prevention of contrast nephropathy.
    Azmus AD; Gottschall C; Manica A; Manica J; Duro K; Frey M; Bulcão L; Lima C
    J Invasive Cardiol; 2005 Feb; 17(2):80-4. PubMed ID: 15687530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?
    Kefer JM; Hanet CE; Boitte S; Wilmotte L; De Kock M
    Acta Cardiol; 2003 Dec; 58(6):555-60. PubMed ID: 14713182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial.
    Carbonell N; Blasco M; Sanjuán R; Pérez-Sancho E; Sanchis J; Insa L; Bodí V; Núñez J; García-Ramón R; Miguel A
    Int J Cardiol; 2007 Jan; 115(1):57-62. PubMed ID: 16814414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.
    Miner SE; Dzavik V; Nguyen-Ho P; Richardson R; Mitchell J; Atchison D; Seidelin P; Daly P; Ross J; McLaughlin PR; Ing D; Lewycky P; Barolet A; Schwartz L
    Am Heart J; 2004 Oct; 148(4):690-5. PubMed ID: 15459602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.
    Huber W; Eckel F; Hennig M; Rosenbrock H; Wacker A; Saur D; Sennefelder A; Hennico R; Schenk C; Meining A; Schmelz R; Fritsch R; Weiss W; Hamar P; Heemann U; Schmid RM
    Radiology; 2006 Jun; 239(3):793-804. PubMed ID: 16714461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
    Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
    Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
    Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
    Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.
    Gomes VO; Poli de Figueredo CE; Caramori P; Lasevitch R; Bodanese LC; Araújo A; Röedel AP; Caramori AP; Brito FS; Bezerra HG; Nery P; Brizolara A
    Heart; 2005 Jun; 91(6):774-8. PubMed ID: 15894775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
    Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
    Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography.
    Gulel O; Keles T; Eraslan H; Aydogdu S; Diker E; Ulusoy V
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):464-7. PubMed ID: 16160598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
    J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
    Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
    JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.